These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9652385)

  • 1. Failure of buparvaquone (Butalex) in the treatment of canine visceral leishmaniosis.
    Vexenat JA; Croft SL; Furtado Campos JH; Miles MA
    Vet Parasitol; 1998 May; 77(1):71-3. PubMed ID: 9652385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy of canine leishmaniosis.
    Baneth G; Shaw SE
    Vet Parasitol; 2002 Jul; 106(4):315-24. PubMed ID: 12079737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical recovery and limited cure in canine visceral leishmaniasis treated with aminosidine (paromomycin).
    Vexenat JA; Olliaro PL; Fonseca de Castro JA; Cavalcante R; Furtado Campos JH; Tavares JP; Miles MA
    Am J Trop Med Hyg; 1998 Apr; 58(4):448-53. PubMed ID: 9574790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concentrations of buparvaquone in milk and tissue of dairy cows.
    McDougall S; Hillerton JE; Pegram D
    N Z Vet J; 2016 Nov; 64(6):318-23. PubMed ID: 27373797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of bovine tropical theileriosis with buparvaquone.
    Sharma NN; Mishra AK
    Trop Anim Health Prod; 1990 Feb; 22(1):63-5. PubMed ID: 2321263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of different treatment regimens of marbofloxacin in canine visceral leishmaniosis: a pilot study.
    Rougier S; Vouldoukis I; Fournel S; Pérès S; Woehrlé F
    Vet Parasitol; 2008 May; 153(3-4):244-54. PubMed ID: 18337012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic efficacy of buparvaquone (buparvon) in cattle with theileriosis].
    Saruhan B; Paşa S
    Turkiye Parazitol Derg; 2008; 32(4):317-21. PubMed ID: 19156603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biogenic nanoporous silicon carrier improves the efficacy of buparvaquone against resistant visceral leishmaniasis.
    Thapa R; Mondal S; Riikonen J; Rantanen J; Näkki S; Nissinen T; Närvänen A; Lehto VP
    PLoS Negl Trop Dis; 2021 Jun; 15(6):e0009533. PubMed ID: 34185780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nodular lesions of the tongue in canine leishmaniosis.
    Parpaglia ML; Vercelli A; Cocco R; Zobba R; Manunta ML
    J Vet Med A Physiol Pathol Clin Med; 2007 Oct; 54(8):414-7. PubMed ID: 17877582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and serological follow-up in dogs with visceral leishmaniosis treated with allopurinol and sodium stibogluconate.
    Pasa S; Toz SO; Voyvoda H; Ozbel Y
    Vet Parasitol; 2005 Mar; 128(3-4):243-9. PubMed ID: 15740861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of canine Old World visceral leishmaniasis: a systematic review.
    Noli C; Auxilia ST
    Vet Dermatol; 2005 Aug; 16(4):213-32. PubMed ID: 16101793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of the treatment of dogs with leishmaniosis with a combination of metronidazole and spiramycin.
    Pennisi MG; De Majo M; Masucci M; Britti D; Vitale F; Del Maso R
    Vet Rec; 2005 Mar; 156(11):346-9. PubMed ID: 15789648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of the sesquiterpene (-)-α-bisabolol in dogs with naturally acquired canine leishmaniosis: an exploratory clinical trial.
    Corpas-López V; Merino-Espinosa G; Acedo-Sánchez C; Díaz-Sáez V; Navarro-Moll MC; Morillas-Márquez F; Martín-Sánchez J
    Vet Res Commun; 2018 Jun; 42(2):121-130. PubMed ID: 29453596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and tolerance of miltefosine in the treatment of canine leishmaniosis.
    Woerly V; Maynard L; Sanquer A; Eun HM
    Parasitol Res; 2009 Aug; 105(2):463-9. PubMed ID: 19322588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical trial of buparvaquone in the treatment of East Coast fever.
    Dolan TT; Injairu R; Gisemba F; Maina JN; Mbadi G; Mbwiria SK; Mulela GH; Othieno DA
    Vet Rec; 1992 Jun; 130(24):536-8. PubMed ID: 1441098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of different tissue sampling for PCR-based diagnosis and follow-up of canine visceral leishmaniosis.
    Manna L; Vitale F; Reale S; Caracappa S; Pavone LM; Morte RD; Cringoli G; Staiano N; Gravino AE
    Vet Parasitol; 2004 Nov; 125(3-4):251-62. PubMed ID: 15482882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Butalex in field cases of bovine theileriosis--short communication.
    Mishra AK; Sharma NN; Viswanathan CB
    Acta Vet Hung; 1993; 41(3-4):361-3. PubMed ID: 8017239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of experimentally induced Theileria annulata infection in cross-bred calves with buparvaquone.
    Dhar S; Malhotra DV; Bhushan C; Gautam OP
    Vet Parasitol; 1988 Mar; 27(3-4):267-75. PubMed ID: 3369076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis.
    Murray HW; Hariprashad J
    Antimicrob Agents Chemother; 1996 Mar; 40(3):586-7. PubMed ID: 8851575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs.
    Garnier T; Mäntylä A; Järvinen T; Lawrence J; Brown M; Croft S
    J Antimicrob Chemother; 2007 Oct; 60(4):802-10. PubMed ID: 17715126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.